| Julia H Murray, | |
|
4800 Sand Point Way Ne, Seattle, WA 98105-3901 | |
| (206) 987-2000 | |
| Not Available |
| Full Name | Julia H Murray |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 4800 Sand Point Way Ne, Seattle, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003992785 | NPI | - | NPPES |
| 5772 | Other | INTERNAL ID-MOTOR VEHICLE ID | |
| 8269284 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD00021446 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Julia H Murray, 4500 Sand Point Way Ne, #100, Seattle, WA 98105-3900 Ph: () - | Julia H Murray, 4800 Sand Point Way Ne, Seattle, WA 98105-3901 Ph: (206) 987-2000 |
News Archive
Endo Pharmaceuticals today announced the successful completion of the tender offer by its indirect wholly owned subsidiary, West Acquisition Corp., for all of the outstanding shares of common stock of Penwest Pharmaceuticals Co.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
Genome-wide epigenomic screening can pinpoint disease-associated variants and identify novel genetic-epigenetic interactions in autoimmune thyroid diseases, according to new data presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada.
Rember—the blue dye that created a stir in 2008 when Phase 2 clinical trial data claimed that it slowed decline in people with Alzheimer's disease—has now been revamped for Phase 3 testing in another disease, behavioral-variant frontotemporal dementia (bvFTD).
When cells experience DNA damage, they'll try to repair it. But if that fails, the damaged cells are supposed to self-destruct, a process called apoptosis. A cancer researcher at Robarts Research Institute at The University of Western Ontario has identified a protein that regulates apoptosis, a new discovery which has implications for both the diagnosis and treatment of cancer. Caroline Schild-Poulter's findings are now published online in the journal Molecular Cancer Research.
› Verified 8 days ago
Dr. Herbert Orenstein, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 901 Boren Avenue, #702, Seattle, WA 98104 Phone: 206-623-7444 Fax: 206-623-7445 | |
Dr. Rebecca Mae Allen, MD, MPH Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 805 Madison St Ste 401, Seattle, WA 98104 Phone: 206-467-6300 | |
Monica Kristin Samelson, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1613 E Alder St, Seattle, WA 98122 Phone: 206-558-5495 | |
Roy D Clark Jr., MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 509 Olive Way, #531, Seattle, WA 98101 Phone: 206-682-5203 Fax: 206-682-5304 | |
Marcio A Sotero De Menezes, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 600 Broadway Ste 400, Seattle, WA 98122 Phone: 206-215-1440 Fax: 206-215-1441 | |
Dr. Lee-loung Liou, MD, PHD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St, C212, Box 356340, Seattle, WA 98195 Phone: 206-543-0065 |